Sun Pharma to acquire Organon in an all-cash transaction worth $11.75 billion Enterprise Value

Shareholders of Organon will be liable to receive $14 per share in cash, which is a 24% premium to the stock’s closing price on Friday. Shares of Organon have already doubled in value since April 8 this year, when reports of this transaction first began to surface. This includes a 30% jump in the stock last Friday itself.

Leave a Reply

Your email address will not be published. Required fields are marked *